Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexJagath R. Junutula, William Mallet, Helga Raab et al.|Nature Biotechnology|2008Cited by 1.4k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen‐Quan Shen, Jagath R. Junutula, Keyang Xu et al.|Nature Biotechnology|2012Cited by 997
Molecular cloning and expression of a receptor for human tumor necrosis factorThomas J. Schall, David V. Goeddel, Martyn Lewis et al.|Cell|1990Cited by 967
Identification of Heregulin, a Specific Activator of p185 <sup>erbB2</sup>William E. Holmes, Richard Vandlen, H. Michael Shepard et al.|Science|1992Cited by 964
Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug SelectionAndrew G. Polson, Allen Ebens, Jill Calemine-Fenaux et al.|Cancer Research|2009Cited by 248